These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30876862)

  • 1. Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain.
    Garić D; De Sanctis JB; Shah J; Dumut DC; Radzioch D
    Prog Lipid Res; 2019 Apr; 74():130-144. PubMed ID: 30876862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain.
    Garić D; De Sanctis JB; Shah J; Dumut DC; Radzioch D
    Prog Lipid Res; 2019 Aug; ():100998. PubMed ID: 31445070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside.
    Garić D; De Sanctis JB; Wojewodka G; Houle D; Cupri S; Abu-Arish A; Hanrahan JW; Hajduch M; Matouk E; Radzioch D
    J Mol Med (Berl); 2017 Oct; 95(10):1053-1064. PubMed ID: 28695226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis.
    Becker KA; Grassmé H; Zhang Y; Gulbins E
    Cell Physiol Biochem; 2010; 26(1):57-66. PubMed ID: 20502005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramide in cystic fibrosis.
    Grassmé H; Riethmüller J; Gulbins E
    Handb Exp Pharmacol; 2013; (216):265-74. PubMed ID: 23563661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chain length-specific properties of ceramides.
    Grösch S; Schiffmann S; Geisslinger G
    Prog Lipid Res; 2012 Jan; 51(1):50-62. PubMed ID: 22133871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-Dependent Progression in Lung Pathophysiology can be Prevented by Restoring Fatty Acid and Ceramide Imbalance in Cystic Fibrosis.
    Youssef M; De Sanctis JB; Shah J; Dumut DC; Hajduch M; Petrof BJ; Radzioch D
    Lung; 2020 Jun; 198(3):459-469. PubMed ID: 32306138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death.
    Becker KA; Tümmler B; Gulbins E; Grassmé H
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):368-74. PubMed ID: 21078296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family.
    Kováčik A; Roh J; Vávrová K
    Chembiochem; 2014 Jul; 15(11):1555-62. PubMed ID: 24990520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceramide and sphingosine in pulmonary infections.
    Seitz AP; Grassmé H; Edwards MJ; Pewzner-Jung Y; Gulbins E
    Biol Chem; 2015 Jun; 396(6-7):611-20. PubMed ID: 25720061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very long chain ceramides interfere with C16-ceramide-induced channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosis.
    Stiban J; Perera M
    Biochim Biophys Acta; 2015 Feb; 1848(2):561-7. PubMed ID: 25462172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceramide in bacterial infections and cystic fibrosis.
    Grassmé H; Becker KA; Zhang Y; Gulbins E
    Biol Chem; 2008 Nov; 389(11):1371-9. PubMed ID: 18783339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramide and the mitochondrial respiratory chain.
    Kogot-Levin A; Saada A
    Biochimie; 2014 May; 100():88-94. PubMed ID: 23933096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipids in cystic fibrosis.
    Becker KA; Henry B; Ziobro R; Riethmüller J; Gulbins E
    Expert Rev Respir Med; 2011 Aug; 5(4):527-35. PubMed ID: 21859272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.
    Teichgräber V; Ulrich M; Endlich N; Riethmüller J; Wilker B; De Oliveira-Munding CC; van Heeckeren AM; Barr ML; von Kürthy G; Schmid KW; Weller M; Tümmler B; Lang F; Grassme H; Döring G; Gulbins E
    Nat Med; 2008 Apr; 14(4):382-91. PubMed ID: 18376404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis: the conductance regulator, ceramides, and possible treatments.
    Luft FC
    J Mol Med (Berl); 2017 Oct; 95(10):1017-1019. PubMed ID: 28831504
    [No Abstract]   [Full Text] [Related]  

  • 17. Ceramide and cystic fibrosis lung disease.
    Brodlie M; Lordan JL; Ward C
    Am J Respir Crit Care Med; 2011 Jan; 183(1):133. PubMed ID: 21193790
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cystic fibrosis, fatty acid imbalance, ceramide and lipid rafts].
    Chanson M
    Arch Pediatr; 2009 Jun; 16(6):543-5. PubMed ID: 19541078
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid composition of airway secretions from patients with asthma and patients with cystic fibrosis.
    Sahu S; Lynn WS
    Am Rev Respir Dis; 1977 Feb; 115(2):233-9. PubMed ID: 842938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CFTR-dependent susceptibility of the cystic fibrosis-host to Pseudomonas aeruginosa.
    Grassmé H; Becker KA; Zhang Y; Gulbins E
    Int J Med Microbiol; 2010 Dec; 300(8):578-83. PubMed ID: 20951085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.